drugset / Trial / NCT06708845
US Zamto-cel Autoimmune Diseases
Non-randomizedSequentialOpen-labelTreatment
Summary
AID is a phase I multi-cohort study to assess the safety and tolerability of zamtocabtagene autoleucel (zamto-cel) in patients with refractory autoimmune diseases (SLE-Non renal, SLE-LN, SSc/dcSSc) after receiving standard therapy.
Timeline
- Start
- 2026-07
- Primary completion
- 2028-01
- Completion
- 2028-07
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | zamtocabtagene autoleucel | Cell therapy | 1e+06 cells/kg | Intravenous |
| Subject | zamtocabtagene autoleucel | Cell therapy | 2.5e+06 cells/kg | Intravenous |
| Background | Cyclophosphamide | Other / unclassified | — | — |
| Background | Fludarabine | Small molecule | — | — |